Three-Year Follow Up Results Confirm Significant Efficacy and No
Serious Adverse Effects in Patients receiving OvaStem® Procedure
for Treating Primary Ovarian Insufficiency
PHOENIX, July 28,
2022 /PRNewswire/ -- Creative Medical Technology
Holdings, Inc. ("Creative Medical Technology" or the "Company")
(NASDAQ: CELZ), a leading commercial stage biotechnology company
focused on a regenerative approach to immunotherapy, urology,
neurology, and orthopedics, today announced positive three-year
follow up data for the Company's OvaStem® pilot study. The
data shows significant efficacy of the OvaStem® procedure for the
treatment of medical refractory Primary Ovarian Insufficiency (POI)
without any serious adverse effects and the successful birth of
healthy babies.
OvaStem® is a patented outpatient clinic procedure that
utilizes a patient's own bone marrow aspirate for treatment of
medical refractory POI. Below is a summary of the study's
three-year follow up data:
There were no safety related concerns at up to three years and
the OvaStem® procedure resulted in an efficacy of 90% in the
treated patients in terms of improvement in hormonal function and
70% in terms of delivery of healthy babies using their own eggs.
Patients with POI usually only have a 5% to 10% chance of
spontaneous pregnancy and must rely on donor eggs for conception
via in vitro fertilization therapy. The company plans to submit a
manuscript for publication in a peer reviewed journal and present
the data at future fertility medicine conferences.
"The positive three-year data from our OvaStem® pilot study
is very encouraging, and we are excited to engage with
practitioners on further development and translation," said
Timothy Warbington, President and
CEO of the company. "To our knowledge, this pilot study is
one of the first to demonstrate the clinical efficacy of injecting
bone marrow aspirate into the ovaries using a minimally invasive
outpatient procedure, thereby repairing, remodeling and improving
the function. We believe as we further develop the OvaStem®
program there is great potential to help patients with POI to
conceive and deliver babies using eggs from their own ovaries
without having to use surrogacy or donor eggs. Despite all on-going
research, there is no FDA approved treatment for POI."
About Creative Medical Technology
Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage
biotechnology company specializing in stem cell technology in the
fields of immunotherapy, urology, neurology, and orthopedics. For
further information about the Company, please visit
www.creativemedicaltechnology.com.
Forward Looking
Statements
This news release may contain forward-looking statements
including but not limited to comments regarding the timing and
content of upcoming clinical trials and laboratory results,
marketing efforts, funding, etc. Forward-looking statements address
future events and conditions and, therefore, involve inherent risks
and uncertainties. Actual results may differ materially from those
currently anticipated in such statements. See the periodic and
other reports filed by Creative Medical Technology Holdings, Inc.
with the Securities and Exchange Commission and available on the
Commission's website at www.sec.gov.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-announces-positive-top-line-results-for-ovastem-pilot-study-301595212.html
SOURCE Creative Medical Technology Holdings, Inc.